Healthcare / BiotechnologyHKSE
$4.50
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-212.7M · quality 69.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
19/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.5B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-18.9%
↓Gross Margin
98.9%
↑Debt/Equity
0.21
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-17.6%
FCF CAGR
—
FCF margin
-397.4%
FCF / Net income
1.46x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $53.5M · net income $-146.0M · FCF $-212.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $53.5M | $53.5M | $155.7M | $63.5M | $95.7M |
| Net Income | $-146.0M | $-146.0M | $-155.7M | $-359.1M | $-371.9M |
| EBITDA | $-110.2M | $-110.2M | $-120.9M | $-325.7M | $-355.8M |
| EPS | -0.19 | -0.19 | -0.20 | -0.46 | -0.49 |
| Gross Margin | 98.9% | 98.9% | 100.0% | 5.0% | 13.2% |
| Operating Margin | -310.6% | -310.6% | -130.5% | -642.7% | -494.8% |
| Net Margin | -272.7% | -272.7% | -100.0% | -565.4% | -388.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.21 | 0.21 | 0.16 | 0.20 | 0.12 |
| Current Ratio | 5.10 | 5.10 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-212.7M | $-212.7M | $-86.2M | $-402.9M | $-308.9M |
| Returns | |||||
| ROE | -18.9% | -18.9% | -16.9% | -33.5% | -29.0% |
| Valuation | |||||
| P/B | 4.52 | 4.52 | 1.06 | 2.56 | 3.32 |
| Growth & Yield | |||||
| Revenue Growth | -65.6% | -65.6% | 145.1% | -33.7% | — |
| EPS Growth | 5.0% | 5.0% | 57.0% | 5.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+2.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.20 → -0.19
Residual
+2.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.